P3, N=80, Recruiting, Soligenix | Not yet recruiting --> Recruiting

P1/2, N=34, Active, not recruiting, Mayo Clinic | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Mar 2024

P1, N=36, Recruiting, Transgene | Trial completion date: Mar 2025 --> Oct 2025 | Trial primary completion date: Oct 2024 --> Apr 2025

P1/2, N=35, Active, not recruiting, Uppsala University | Recruiting --> Active, not recruiting | Trial completion date: Sep 2024 --> Dec 2025 | Trial primary completion date: Aug 2023 --> Aug 2025

P1, N=13, Active, not recruiting, University of Pennsylvania | Recruiting --> Active, not recruiting

Complete response (according to Response Assessment in Neuro-Oncology Criteria) in one patient, a partial response in one patient and post-treatment infiltrations of CD4+ and CD8 + T cells into the tumour were documented during this trial. In conclusion, Ad-TD-nsIL12 has demonstrated safety and preliminary efficacy in patients with recurrent high-grade glioma.

P1, N=18, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Oct 2024 --> Oct 2026 | Trial primary completion date: Oct 2024 --> Oct 2026

P2, N=27, Recruiting, Oslo University Hospital | Not yet recruiting --> Recruiting

MP-10.01 Diffusion-Weighted Magnetic Resonance Imaging for Assessment of Tumor Response in Muscle-Invasive Bladder Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Prospective StudyAbbas Basiri, Iran, Islamic Rep. MP-10.02 Divergent Experiences of Bladder Cancer Patients: A Focus on Advanced and Metastatic Disease StagesAlex Filicevas, Belgium MP-10.03 Evolution of a Rapid, Simple Urine Test for Detecting Volatile Organic Compound (VOC) in Urine by a High Performance Portable Device (NABIL) for Detection of Urinary Bladder CarcinomaSaurav Karmakar, India MP-10.04 Intraoperative ICG Fluorescence as a Method of Prevention of Postoperative Strictures of Uretero-Ileoanastomoses During Robot-Assisted Radical CystectomyValentin Pavlov, Russian Federation MP-10.05 Intravesical Gemcitabine and Docetaxel in Patients with High Risk NMIBC: Our ExperienceDeepak Krishnappa, India MP-10.06 On Block Robot-Assisted Radical Cystectomy: New Method for Bladder CancerValentin Pavlov, Russian Federation MP-10.07 Oncological Outcomes with the 80mg Dose of the Moscow Strain of Intravesical BCG for Non-Muscle Invasive Bladder Cancer: Implications for Global ShortageAmandeep Arora, India MP-10.08 Outcome of Robot-Assisted Radical Cystectomy with Intracorporeal Creation of Heterotopic NeocystisValentin Pavlov, Russian Federation MP-10.09 Proposed Novel Surveillance Schedule Using Cx Monitor for Patients on Annual Bladder Cancer SurveillanceArjun Guduguntla, Australia MP-10.10 Quality of Primary TURBTs for Non-Muscle Invasive Bladder Cancer PatientsSaurabh Verma, United Kingdom MP-10.11 TAR-200 in Patients with Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results from the SunRISe-1 StudyAndrea Necchi, United States MP-10.12 Timeline Analysis of Muscle Invasive Bladder Cancer PatientsSaurabh Verma, United Kingdom MP-10.13 Transurethral Resection of Bladder Tumour (TURBT) Operative Notes: How to Improve Their QualitySaurabh Verma, United Kingdom MP-10.14 Trial in Progress: PIVOT-006- A Phase 3, Randomized Study of Adjuvant Intravesical Cretostimogene Grenadenorepvec versus Surveillance for the Treatment of Intermediate-Risk Non-Muscle Invasive Bladder Cancer Following Transurethral Resection of Bladder TumorRobert Svatek, United States MP-10.15 URO17® Urine Test For Bladder Cancer - Meta AnalysisNikhil Vasdev, United Kingdom MP-10.16 Usefulness of UF-5000 Automatic Screening System in Urothelial Carcinoma DiagnosisTadahiko Kikugawa, Japan MP-10.17 Validation of Novel ddPCR Bladder Cancer DNA Mutation Panels in Liquid BiopsiesAntara Karmakar, Australia

P2, N=27, Not yet recruiting, Oslo University Hospital

P2, N=92, Completed, Verrica Pharmaceuticals Inc. | Recruiting --> Completed

Our data provide additional insight into mitochondrial stress and ICD in response to PT-112. PT-112 anticancer immunogenicity could have clinical applications and is currently under investigation in a Phase 2 mCRPC study.

P2, N=96, Active, not recruiting, Theriva Biologics SL | Recruiting --> Active, not recruiting

P2, N=50, Recruiting, CG Oncology, Inc. | Not yet recruiting --> Recruiting

P1, N=9, Completed, Mayo Clinic | Recruiting --> Completed | N=30 --> 9 | Trial completion date: Sep 2024 --> Apr 2024 | Trial primary completion date: Sep 2024 --> Apr 2024

P1/2, N=0, Withdrawn, Ectin Research AB | N=50 --> 0 | Trial completion date: Dec 2024 --> Dec 2025 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2024 --> Dec 2025

P2, N=35, Completed, CG Oncology, Inc. | Active, not recruiting --> Completed | Trial completion date: Jun 2023 --> May 2024

P1, N=27, Suspended, Boehringer Ingelheim | Trial completion date: Nov 2025 --> Jan 2027 | Recruiting --> Suspended | Trial primary completion date: Nov 2024 --> Jan 2026

YBX1 mRNA levels were significantly correlated with cyclin A1 mRNA levels in patients with high-grade serous carcinoma. Augmented YBX1 expression plays a key role in tumor growth promotion in ovarian cancer in its close association with cyclin A1.

P=N/A, N=0, Available, Replimune Inc.

These promising results encourage future research to optimize sonoporation parameters for clinical use, investigate synergistic effects with existing treatments, and assess long-term safety and efficacy in vivo. Our study highlights CaSP's clinical potential for improved safety and efficacy in cancer therapy, offering significant implications for the pharmaceutical and biomedical fields.

P=N/A, N=13, Completed, Fundació Sant Joan de Déu | Active, not recruiting --> Completed

P2, N=50, Not yet recruiting, CG Oncology, Inc.

P1, N=45, Recruiting, Tongji Hospital

P2, N=48, Completed, Armata Pharmaceuticals, Inc. | Recruiting --> Completed

P1, N=30, Recruiting, Tongji Hospital | Not yet recruiting --> Recruiting

P3, N=400, Recruiting, Replimune Inc. | Not yet recruiting --> Recruiting

P1, N=12, Active, not recruiting, Aummune Ltd. | Recruiting --> Active, not recruiting | Trial completion date: Jun 2024 --> Jan 2025

TG6050 effectively delivers functional IL-12 and @CTLA-4 into the tumor, resulting in strong antitumor activity. The shift towards an inflamed TME correlated with a boost in systemic antitumor T cells. The solid preclinical data and favorable benefit/risk ratio paved the way for the clinical evaluation of TG6050 in metastatic non-small cell lung cancer (NCT05788926 trial in progress).

P1, N=49, Recruiting, Affiliated Cancer Hospital of Shandong First Medical University; Shanghai Yuansong Biotechnology Co., LTD.

P2, N=10, Completed, Soligenix | Recruiting --> Completed

Considering the heterogeneity of PDAC and the complexity of biological therapies such as OVs, no single biomarker can explain the spectrum of response patterns. For selection of a particular OV, PDAC molecular subtype, ISG expression as well as activation of distinct signaling and metabolic pathways should be considered. Combination therapies can overcome resistance in specific constellations. Overall, oncolytic virotherapy is a viable treatment option for PDAC, which warrants further development. This study highlights the need for personalised treatment in OVT. By providing all primary data, this study provides a rich source and guidance for ongoing developments.

P3, N=80, Not yet recruiting, Soligenix

The bi-specific siRNA strategy, encapsulated in an adenovirus, could be a promising tool to augment cancer treatment efficacy and overcome conventional therapy limitations associated with "undruggability." Hence, we propose that dual targeting of mTOR and STAT3 is an advantageous strategy for intravesical therapy using adenoviruses.

P1/2, N=34, Active, not recruiting, Mayo Clinic | Recruiting --> Active, not recruiting | N=57 --> 34

P=N/A, N=0, Available, CG Oncology, Inc.

P1/2, N=51, Recruiting, Institut Curie | Not yet recruiting --> Recruiting | Initiation date: Dec 2023 --> Apr 2024

The study shows that YSCH-01 injections were safe and well tolerated and exhibited preliminary efficacy in patients with advanced solid tumors, supporting further investigation to evaluate its efficacy and safety.

Purpose/Objective: The CEDAR trial was a multi-centre phase 1 clinical trial (NCT03916510) in locally advanced rectal cancer patients which combined 25x2Gy chemoradiation with concurrent capecitabine and Enadenotucirev (EnAd), a tumourselective intravenous oncolytic adenovirus. S5230 Radiobiology - Microenvironment Interpatient microbial heterogeneity is greater than dynamic microbiome shifts through treatment in this study. Certain microbiome constituents may be associated with more favourable radiation responses. The absence of significant microbial variation during treatment suggests baseline microbiome features could be further explored as a predictive biomarker.

P3, N=190, Recruiting, CG Oncology, Inc. | N=110 --> 190 | Trial completion date: Jul 2025 --> Dec 2029 | Trial primary completion date: Jan 2024 --> Dec 2027

The TSRP is composed of: i) Recognition unit could specifically target and inhibit the biological function of FGFR-1; ii) Transformable unit could self-assembly and trigger nanofibers formation; iii) Reactive unit could specifically cleaved by MMP-2/9 in tumor micro-environment; iv) Immune unit, stimulate the release of immune cells when LTX-315 (Immune-associated oncolytic peptide) exposed...All above processes together contribute to the increasing survival rate of tumor-bearing mice by nearly 4-folds. This work presented a unique design for the biological application of one-step synergistic therapy of bladder cancer.

P2, N=42, Recruiting, Soligenix | Trial completion date: Dec 2023 --> Jun 2025 | Trial primary completion date: Oct 2023 --> Apr 2025